Invention facilitates treatment of larger
tumors and is a significant leap forward in the field of
cryoablation
CAESAREA, Israel, Nov. 25,
2024 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:
ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of
minimally-invasive cryoablation technology that destroys tumors by
freezing as an alternative to surgical tumor removal, today
announced it has received a Notice of Allowance from the Japan
Patent Office for its invention titled 'Cryogenic System with
Multiple Submerged Pumps'.
The patent addresses a cryogenic system featuring multiple
submerged pumps that enable IceCure to introduce a groundbreaking
next-generation multiprobe system. This advanced technology allows
for high-end capabilities to independently control and maintain the
performance of each cryoprobe, facilitating the treatment of large
tumors.
"As a core technology for our next-generation MSense™ multiprobe
cryoablation system, we believe that our latest innovation not only
expands our intellectual property and product portfolio, but also
represents a significant leap forward in the field of cryoablation
procedures," stated IceCure's Chief Executive Officer, Eyal Shamir. "Japan is a market in which we are active
through our partner, Terumo Corporation, which plans to file for
regulatory approval of ProSense® for breast cancer in 2025."
About IceCure Medical
IceCure Medical (Nasdaq: ICCM) develops and markets advanced
liquid-nitrogen-based cryoablation therapy systems for the
treatment of tumors (benign and cancerous) by freezing, with the
primary focus areas being breast, kidney, bone and lung cancer. Its
minimally invasive technology is a safe and effective alternative
to hospital surgical tumor removal that is easily performed in a
relatively short procedure. The Company's flagship ProSense® system
is marketed and sold worldwide for the indications cleared and
approved to date including in the U.S., Europe and China.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995 and other Federal
securities laws. Words such as "expects," "anticipates," "intends,"
"plans," "believes," "seeks," "estimates" and similar expressions
or variations of such words are intended to identify
forward-looking statements. For example, IceCure is using forward
looking statements in this press release when it discusses: the
potential use of the patent; the belief that this patent represents
a significant leap forward in the field of cryoablation technology;
and that Terumo Corporation plans to file for regulatory approval
of ProSense® for breast cancer in 2025. Historical results of
scientific research and clinical and preclinical trials do not
guarantee that the conclusions of future research or trials will
suggest identical or even similar conclusions. Important factors
that could cause actual results, developments and business
decisions to differ materially from those anticipated in these
forward-looking statements include, among others: the Company's
planned level of revenues and capital expenditures; the Company's
available cash and its ability to obtain additional funding; the
Company's ability to market and sell its products; legal and
regulatory developments in the United
States and other countries; the Company's ability to
maintain its relationships with suppliers, distributors and other
partners; the Company's ability to maintain or protect the validity
of its patents and other intellectual property; the Company's
ability to expose and educate medical professionals about its
products; political, economic and military instability in the
Middle East, specifically in
Israel; as well as those factors
set forth in the Risk Factors section of the Company's Annual
Report on Form 20-F for the year ended December 31, 2023 filed with the SEC on
April 3, 2024, and other documents
filed with or furnished to the SEC which are available on the SEC's
website, www.sec.gov. The Company undertakes no obligation to
update these statements for revisions or changes after the date of
this release, except as required by law.
IR Contact:
Email: investors@icecure-medical.com
Michael Polyviou
Phone: 732-232-6914
Todd Kehrli
Phone: 310-625-4462
Logo:
https://mma.prnewswire.com/media/2319310/IceCure_Medical_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/icecures-next-generation-multiprobe-cryoablation-technology-issued-notice-of-allowance-from-japans-patent-office-302315246.html
SOURCE IceCure Medical